If you have been reading about PT-141 code and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-05. Numbers and descriptions here follow the published literature rather than marketing material.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
== V == VAMAS6 - vanillin synthase - VanY protein domain - Var1 protein domain - vax2os1 - vector - VEK-30 protein domain - vinorine hydroxylase - vitamin B12-transporting ATPase - vitamin D binding protein domain III - vitelline membrane outer layer protein I (VMO-I) -
== Implementation == The Carter Center, who was appointed as the independent observer of the agreement's implementations in 2017, stated that 22% of the accords' provisions were put into effect by 2017, and by 2020, that number had only increased to 23%. While the Malian Army was dispatched to Kidal as per the terms of the agreement, the troops never actually patrolled the city. Similarly, CMA fighters were sent to Gao under similar provisions. Part of the reason for the lack of implementation was the need for more willingness by the signatories to honor it. A March 2020 survey showed slightly over eighty percent of Malian civilians had little to no knowledge of the peace agreement. The CMA continued to exercise de facto control over the Kidal region, which the Malian government tolerated as Malian government control of the region would force the government to enact constitutional reforms upending the status quo.
Each PLA probes comes with a unique short DNA strand attached to it and bind either to species specific primary antibodies or consist of directly DNA-labeled primary antibodies. When the PLA probes are in close proximity, the DNA strands can interact through a subsequent addition of two other circle-forming DNA oligonucleotides. After joining of the two added oligonucleotides by enzymatic ligation, they are amplified via rolling circle amplification using a polymerase. After the amplification reaction, several-hundredfold replication of the DNA circle has occurred and flurophore or enzyme labeled complementary oligonucleotide probes highlight the product. The resulting high concentration of fluorescence or cromogenic signal in each single-molecule amplification product is easily visible as a distinct bright spot when viewed with either in a fluorescence microscope or a standard brightfield microscope.
Sources: en.wikipedia.org
octanol-water partition coefficient log P not greater than 3 molecular mass less than 300 daltons not more than 3 hydrogen bond donors not more than 3 hydrogen bond acceptors not more than 3 rotatable bonds
The availability of GFP and its derivatives has thoroughly redefined fluorescence microscopy and the way it is used in cell biology and other biological disciplines. While most small fluorescent molecules such as FITC (fluorescein isothiocyanate) are strongly phototoxic when used in live cells, fluorescent proteins such as GFP are usually much less harmful when illuminated in living cells. This has triggered the development of highly automated live-cell fluorescence microscopy systems, which can be used to observe cells over time expressing one or more proteins tagged with fluorescent proteins. There are many techniques to utilize GFP in a live cell imaging experiment. The most direct way of utilizing GFP is to directly attach it to a protein of interest. For example, GFP can be included in a plasmid expressing other genes to indicate a successful transfection of a gene of interest. Another method is to use a GFP that contains a mutation where the fluorescence will change from green to yellow over time, which is referred to as a fluorescent timer. With the fluorescent timer, researchers can study the state of protein production such as recently activated, continuously activated, or recently deactivated based on the color reported by the fluorescent protein. In yet another example, scientists have modified GFP to become active only after exposure to irradiation giving researchers a tool to selectively activate certain portions of a cell and observe where proteins tagged with the GFP move from the starting location.
In 1981 Channon left Guy's Hospital to continue his work with Drs Martin Hartog and Richard Paisey at the Bristol Royal Infirmary. Channon then developed the miniature Portaject device. Unlike the Multiject the Portaject is designed to be worn. It has the capacity for sufficient insulin for 24 hours (at the time insulin had to be refrigerated; at room or body temperature it would become unusable after 24 hours). Channon self-funded the design and fabrication work through his company Channon Medical Ltd. He filed a patent for the Portaject in 1988 but subsequently withdrew the application, choosing instead to donate his research to the field. Clinical trials at the BRI were supported by a small grant of £4,500 from the National Medical Research fund. Dr Hartog attests that "Portaject was the first device that allowed convenient repeated subcutaneous injections of insulin and led to the Novopen. Administration of insulin in this way resulted in a much improved control of the patient's diabetes and, consequently, to a considerably improved prognosis overall". Dr Paisey recalls that clinical trials were conducted with 20 patients and that "one of them continued for 20 years with the same device and achieved good glycemic control. He also designed and manufactured a belt to house the pump". Another long term user, Stephen Dixon, wrote to Channon "Thanks so much for doing what you did. You truly helped transform millions of lives, including mine". In 1989 Channon developed a simple device for protecting, lubricating and sterilizing a hypodermic needle.
CIVIL RECORDS Held in the 20 arrondissement town halls: Births from 1925 to the present. Marriages from 1948 to the present. Deaths from 1987 to the present. Available at the Paris Archives: Before 1860: Births, marriages, and deaths from the 16th century to 1859—alphabetical-chronological indexes and records of the so-called “reconstructed” civil status from former parishes of Paris, the 12 former arrondissements, and fully or partially annexed communes in 1860. From 1860 onwards: Decennial tables: Births, marriages, and deaths up to 1932. Marriages from 1955 to 1974. Deaths from 1955 to 1984. Annual tables: Marriages from 1933 to 1954 (only record numbers are listed). Deaths from 1933 to 1954 (only record numbers are listed) and from 1985–1986. Records: Births up to 1922. Marriages up to 1947. Deaths up to 1986. Available on-site at the Paris Archives: Records from the second reconstruction (V.5.E). 29 registers of parish or civil status records from the 18th and 19th centuries not destroyed in 1871 (V.6.E 1–29). Births from 1923 and 1924. CATHOLIC RECORDS Baptisms, marriages, and burials from the 16th century to 1792—about 50 parish registers, mostly containing excerpts, preserved at the National Archives and the National Library. Baptisms, marriages, and burials from all Parisian churches from 1793 to 1909 (with gaps): First copies preserved in parishes (a single register for burials). Second copies (baptisms and marriages only) deposited at the Paris Archives by the Archdiocese.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.